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Abstract
Purpose: We explored the potential overall survival (OS) benefit of bleomycin, 
etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), 
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procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, 
vinblastine, and dacarbazine (ABVD) in a pooled analysis of four randomized trials.
Patients and methods: Primary objective was to evaluate the OS impact of BEACOPP 
using individual patient data. Secondary objectives were progression-free survival 
(PFS), secondary cancers, and use of autologous stem cell transplantation (ASCT).
Results: About 1227 patients were included. The 7-year OS was 84.3% (95% CI 
80.8-87.2) for ABVD vs 87.7% (95% CI 84.5-90.2) for BEACOPP. Two follow-up 
periods were identified based on survival curves and hazard ratio (HR) over time. For 
the first 18 months, there was no difference. For the second period of ≥18 months, 
ABVD patients had a higher death risk (HRABVD vs BEACOPP = 1.59; 95% CI 1.09-
2.33). A Cox model stratified by trial and evaluating the effect of treatment and 
International Prognostic Index (IPI) score as fixed effects showed that both were sta-
tistically significant (treatment, P = .0185; IPI score, P = .0107). The 7-year PFS was 
71.1% (95% CI 67.1-74.6) for ABVD vs 81.1% (95% CI 77.5-84.2) for BEACOPP 
(P < .001). After ABVD, 25 secondary cancers (4.0%) were reported with no my-
elodysplasia (MDS)/acute myeloid leukemia (AML) compared to 36 (6.5%) after 
BEACOPP, which included 13 patients with MDS/AML. Following ABVD, 86 pa-
tients (13.8%) received ASCT vs 39 (6.4%) for BEACOPP.
Conclusions: This analysis showed a slight improvement in OS for BEACOPP and 
confirmed a PFS benefit. Frontline use of BEACOPP instead of ABVD increased 
secondary leukemia incidence but halved the requirement for ASCT.
K E Y W O R D S
ABVD, BEACOPP, Hodgkin lymphoma, overall survival, progression-free survival, secondary 
cancers
1 |  INTRODUCTION
Hodgkin lymphoma (HL) is one of the most curable adult 
cancers, with long-term cure rates of >80% achieved even 
in patients with advanced disease.[1] The combination of 
doxorubicin (Adriamycin), bleomycin, vinblastine, and 
dacarbazine (ABVD) is a current standard of care but is 
challenged by the German Hodgkin Study Group (GHSG) 
who developed a combination consisting of bleomycin, 
etoposide, doxorubicin (Adriamycin), cyclophospha-
mide, vincristine (Oncovin), procarbazine, and predni-
sone (BEACOPP). The HD9 trial conducted by the GHSG 
demonstrated the superiority of BEACOPP compared to 
cyclophosphamide, vincristine (Oncovin), procarbazine, 
and prednisone alternating with ABVD (COPP-ABVD) 
both in terms of failure-free survival and overall survival 
(OS).[2] As COPP/ABVD used in the HD9 trial was not a 
standard regimen and because of concerns about the tox-
icity of BEACOPP, several groups have conducted head-
to-head comparisons of ABVD and BEACOPP.[3-7] All 
of these phase III randomized trials showed a benefit for 
BEACOPP in terms of disease control. However, although 
the OS estimates were in favor of BEACOPP, they never 
reached statistical significance in each individual trial. 
After screening the literature, we confirmed four random-
ized trials comparing ABVD and BEACOPP. We pooled 
the individual patient data from these trials to evaluate OS 
with an increased statistical power and, also, with a longer 
median follow-up.
2 |  PATIENTS AND METHODS
2.1 | Study selection and data extraction
We searched the following databases without any language 
restrictions: the Cochrane Library including the Cochrane 
Central Register of Controlled Trials, Medline (Ovid: 
January 1980-June 2016), and conference proceedings of 
annual meetings of the American Society of Hematology, 
American Society of Clinical Oncology, and European 
Hematology Association if not included in CENTRAL. 
Two independent investigators (JDe and JDo) selected 
studies. Both investigators screened the titles and abstracts 
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of study reports identified by the search strategy for eligi-
bility. Disagreements were resolved by discussion with a 
third author (MA).
We only included phase III randomized controlled tri-
als in adult patients with newly diagnosed advanced-stage 
HL, as defined by the investigators, assessing any of the 
following prespecified interventions: BEACOPPbaseline, 
BEACOPPescalated, BEACOPP variants (ie four cycles of 
BEACOPPescalated [4-BEACOPPescalated] followed by two 
or four cycles of BEACOPPbaseline [2-BEACOPPbaseline or 
4-BEACOPPbaseline]), and ABVD. Trial reports had to provide 
data on OS for inclusion irrespective of follow-up duration.
After this literature review, four individual patient data 
corresponding to the selection criteria were identified: 
HD2000,[3,7] Italian Intergroup on Lymphoma (IIL),[4] 
H34 low risk,[5] and EORTC20012[6]). In HD2000, 
patients received six courses of ABVD (6-ABVD) vs 
4-BEACOPPescalated plus 2-BEACOPPbaseline. In IIL, pa-
tients received 6-ABVD vs 4-BEACOPPescalated plus 
4-BEACOPPbaseline. In H34 low risk, patients received eight 
courses of ABVD (8-ABVD) vs 4-BEACOPPescalated plus 
4-BEACOPPbaseline. In EORTC20012, patients received 
8-ABVD vs 4-BEACOPPescalated plus 4-BEACOPPbaseline. 
Follow-up was short in the original reports of the studies 
H34 low risk[5] and EORTC20012,[6] so data were updated 
for longer follow-up conducted in March 2017 for these two 
studies. For the HD2000 study,[3] an update with a longer 
follow-up was recently published[7] and was used in our cur-
rent analysis. The data of the IIL study[4] could not be up-
dated for follow-up due to regulatory issues.
All patients provided written, informed consent before en-
rolment in each study. The study was approved the CHU UCL 
Namur Ethics Committee and was done in accordance with 
the Declaration of Helsinki and the International Conference 
on Harmonization Guidelines for Good Clinical Practice.
2.2 | Study objectives
The primary objective was to evaluate the impact of BEACOPP 
vs ABVD on OS. Secondary objectives were to compare pro-
gression-free survival (PFS), secondary cancers, causes of 
death, and use of high-dose chemotherapy with autologous 
stem cell transplantation in relapsing or refractory patients. OS 
and PFS were defined as the time from the date of randomiza-
tion to the date of death from any cause and to the date of dis-
ease progression or death from any cause, respectively.
2.3 | Statistical analysis
Individual participant data obtained from the authors of the 
original studies were used for analyses. OS and PFS were 
analyzed according to randomized treatment arm for the 
intent-to-treat populations. Intent-to-treat population was de-
fined as: all randomized patients (even if later found to be 
ineligible) with informed consent in IIL, H34 low risk, and 
EORTC200012; and all patients excluding patients for whom 
an exclusion criterion was discovered after random assign-
ment and patients who had insufficient follow-up informa-
tion to determine treatment outcome in HD2000. The safety 
population was defined as all patients enrolled in the study 
who started the allocated protocol therapy.
The types of events taken into account for survival anal-
ysis were described in numbers and percentages. Survival 
estimates resulting from Kaplan-Meier survival analysis and 
hazard rate over time were presented graphically. Multivariate 
analysis was performed using a Cox regression model strat-
ified by trial. The median time-to-event was estimated with 
95% confidence intervals (CIs). In addition, the event rates 
at specific time points were computed along with 95% CIs. 
Estimates of the treatment effect were expressed as hazard 
ratios (HRs) with 95% CIs. All tests were two-sided and per-
formed at a significance level of 5%.
3 |  RESULTS
The four selected trials recruited 1227 patients (622 ABVD 
and 605 BEACOPP). Patient characteristics are summarized 
in Table  1 and are well balanced between the two arms. 
Median age was 32 years (range 15-67) with a male predomi-
nance (63.9%). A total of 86.9% patients were stage III-IV; 
patients with stage II high risk could be included in the IIL 
and HD2000 studies alone and represented 12.9% of all pa-
tients. Overall, 37.8% of the population had bulky disease and 
65.9% had International Prognostic index (IPI) score ≥ 3.[8] 
Median (95% CI) follow-up for all patients included in this 
analysis was 7 (6.6-7.2) years and was similar in both arms. 
It was 10 (9.3-10.3)  years in the HD2000 study, 5.1 (4.7-
5.2) years in the IIL study, 7.7 (6.5-8.5) years in the H34 low 
risk study, and 7.6 (7.1-8.0) years in the EORTC20012 study.
3.1 | Primary endpoint: OS
OS analysis was performed on the four studies and 166 deaths 
(13.5%) were reported. The 7-year OS was 84.3% (95% CI 
80.8-87.2) in the ABVD arm vs 87.7% (95% CI 84.5-90.2) 
in the BEACOPP arm; 10-year OS was 80.2% (95% CI 75.7-
84.0) in the ABVD arm vs 84.7% (95% CI 80.5-88.0) in the 
BEACOPP arm (Figure  1). OS by treatment in each study 
is reported in the appendix (Figures S1-S4). As HR was not 
constant over time (Figure  1), two follow-up periods were 
identified based on HR over time: ≤18 vs >18 months after 
randomization. For the first period, patients alive 18 months 
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after randomization were censored at 18 months. For the sec-
ond period, only patients alive 18 months after randomization 
were considered.
3.1.1 | Less than 18 months follow-up 
(N = 1227)
There were 54 deaths (4.4%), with no difference being detected 
between the treatment arms (HRABVD  vs  BEACOPP  =  0.715; 
95% CI 0.417-1.226; P = .22).
3.1.2 | After 18 months follow-up (N = 1128)
There were 112 deaths (9.9%). Patients in the ABVD arm had 
a higher risk of death compared to those in BEACOPP arm: 
HRABVD vs BEACOPP = 1.592; 95% CI 1.088-2.33; P = .0167). 
At 5 years, OS was estimated at 88.3% (95% CI 85.0-90.9) 
in the ABVD arm and 93.2% (95% CI 90.5-95.2) in the 
BEACOPP arm.
Another evaluation performed on two different time 
period (≤30 vs >30  months) showed similar results (see 
Appendix S1).
3.1.3 | Multivariate analysis
An exploratory analysis of the effect of IPI score was also 
performed: 412 patients had a score of 0-2, 797 had a score of 
≥3, and 18 had missing data. The 7-year OS was 92.7% (95% 
CI 89.5-95.0) for IPI score 0-2 and 82.3% (95% CI 79.1-85.1) 
for IPI score ≥3, with an HR of 0.415 (95% CI 0.280-0.613; 
P < .001).
Additionally, a Cox model was constructed stratified by 
trial to evaluate the effect of treatment and IPI score (0-2 vs 
≥3) as fixed effects. Both treatment and IPI score were statis-
tically significant for the period >18 months after randomiza-
tion (treatment effect P = .0185; IPI score P = .0107). Patients 
treated with ABVD had a higher risk of death than patients 
treated with BEACOPP (HRABVD vs BEACOPP = 1.586; 95% CI 
1.081-2.328). A high IPI score (≥3) significantly increased 
the risk of death (HRhigh vs low = 2.284; 95% CI 1.212-4.306).
For the period ≤18  months after randomization, only 
IPI score was significant (treatment effect P  =  .2485, 
HRABVD vs BEACOPP = 0.728, 95% CI = 0.424-1.249; IPI score 
P = .0192, HRhigh vs low = 2.811; 95% CI = 1.183-6.678).
3.1.4 | Causes of death
Causes and number of deaths are reported in Table  2. 
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were from progression of HL. In the ABVD arm, 93 patients 
died: the primary cause of death was HL (n = 57) followed 
by toxicities (n = 15) and secondary cancer (n = 8). In the 
BEACOPP arm, 73 patients died: the primary cause of death 
was secondary cancer (n  =  22, including 10 patients with 
secondary myelodysplasia [MDS]/acute myeloid leukemia 
[AML]), HL progression (n = 21), and toxicities (n = 16).
3.2 | Secondary endpoints
3.2.1 | Progression-free survival
A total of 291 patients (23.7%) had an event (progression/
relapse [n  =  214] and death from any cause [n  =  77]). 
The 7-year PFS was 71.1% (95% CI 67.1-74.6) for ABVD 
vs 81.1% (95% CI 77.5-84.2) for BEACOPP (P  <  .001) 
(Figure 2). Patients in the ABVD arm were more likely to 
relapse, progress, or die than patients in BEACOPP arm 
(HRABVD  vs  BEACOPP  =  1.604, 95% CI 1.267-2.030). PFS 
by treatment in each study is reported in the appendix 
(Figures S5-S8). International Prognostic index score had a 
significant effect on PFS: the HR of IPI score 0-2 was 0.706 
(95% CI 0.545-0.913; P = .007).
3.2.2 | Secondary cancers
Sixty-three secondary cancers occurred during follow-up in 
61 patients (one patient experienced three secondary cancers). 
Secondary cancers are reported in Table 3. The incidence of 
secondary cancers per 1000 person-years was 6.3% (95% CI 
4.29-9.39) in ABVD arm vs 9.6% (95% CI 4.29-13.25) in 
BEACOPP arm. Six cases of solid tumors occurred in pa-
tients who also received previous radiotherapy.
Thirteen cases of secondary MDS/AML were reported in 
the BEACOPP arm compared to none in the ABVD arm. One 
case of AML occurred in a patient who had also received 
radiotherapy and one case of MDS occurred in a patient who 
had undergone ASCT. Twelve non-HLs occurred: eight in 
the ABVD arm and four in the BEACOPP arm. Thirty-three 
solid tumors were reported: 15 in the ABVD arm and 18 in 
the BEACOPP arm.
3.2.3 | Additional treatments
This analysis could only be performed for 882 patients of 
the safety set, as data were not available for the IIL study. 
Additional radiotherapy (planned by protocol in HD2000 or 
within the 3 months following the end of treatment in H34 
studies) after chemotherapy was given to 12.6% and 11.3% 
of the patients in the ABVD and BEACOPP arms, respec-
tively. High-dose chemotherapy with ASCT was used as sec-
ond-line chemotherapy in 61 of 456 patients (13.4%) treated 
with ABVD and in 27 of 426 patients (6.3%) treated with 
BEACOPP.
4 |  DISCUSSION
This analysis compared OS after ABVD vs BEACOPP as 
initial treatment for advanced HL with a median 7-year fol-
low-up for the combined results of four randomized studies. 
We confirmed better initial disease control with BEACOPP 
over ABVD (7-year PFS rate 81.1% vs 71.1%): patients who 
F I G U R E  1  Kaplan-Meier curve for 
overall survival of all patients included 
in the four studies comparing ABVD 
and BEACOPP. ABVD, doxorubicin, 
bleomycin, vinblastine, and dacarbazine; 
BEACOPP, bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, 
procarbazine, and prednisone
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received ABVD were more at risk of relapse, progression, or 
death. As a consequence of this, more patients needed sal-
vage treatment including ASCT, considered as a standard of 
care in this setting,[9] in the ABVD group.
For the analysis of OS, two time periods were defined 
because HR was not constant over time. During the first 
18  months, there was no difference between the regimens. 
After 18 months, a slight difference in OS emerged and is 
restricted to patients surviving 18 months. Importantly, the 
causes of death were different between the treatments. The 
major cause of death in the ABVD group was HL, represent-
ing 61.3% of all deaths. However, the main cause of death in 
the BEACOPP arm was secondary cancer. All 13 cases of 
secondary MDS/AML reported in this study occurred in the 
BEACOPP arm and 10 patients died from this complication.
Eichenauer et al[10] have reviewed MDS/AML as a ther-
apy-related complication, showing patients who received 
four courses of BEACOPPescalated had an increased risk of 
developing AML/MDS compared to those treated with less 
than four cycles of BEACOPPescalated or no BEACOPP che-
motherapy (1.7% vs 0.7% vs 0.3%, P < .0001). The 2.2% 
incidence of MDS/AML in our study, which is slightly 
higher than that reported by the GHSG, emphasizes the 
need to reduce the toxicity of this regimen. The eight cy-
cles of BEACOPP used in the present analysis is no longer 
used following the report by Engert et al[11] that six cy-
cles resulted in lower immediate toxicity and improved OS 
compared to eight cycles when used in combination with 
positron emission tomography (PET)-guided radiotherapy. 
A PET-guided approach has been evaluated by Borchmann 
et al,[12] who randomized patients who were PET nega-
tive after two cycles of BEACOPPescalated to receive either 
four or two additional BEACOPPescalated cycles (a total of 
four BEACOPPescalated cycles in the experimental arm). The 
study showed that, in PET2-negative patients, treatment 
can be reduced to four cycles of BEACOPPescalated without 
loss of tumor control and 3-year OS was 98.8% (95% CI 
97.2-100.0) in the 4-BEACOPPescalated arm. Five patients 
died from secondary MDS/AML in the standard arm com-
pared to one patient in the experimental 4-BEACOPPescalated 
arm. More recently, Casasnovas et al[13] also random-
ized PET2-negative patients between 6-BEACOPPescalated 
v 2-BEACOPPescalated plus 4-ABVD. The primary ob-
jective of the study was to show the noninferiority of 
the 2-BEACOPPescalated plus 4-ABVD arm was met. The 
5-year PFS was 86.2% (95% CI 81.6-89.8) in the standard 
treatment group vs 85.7% (95% CI 81.4-89.1) in the PET-
guided treatment group (HR, 1.084; 95% CI 0.737-1.596; 
P = .65). With a median follow-up of 50 months, one sec-
ondary AML/MDS was reported in each group.
Moving away from BEACOPP, disease control by 
ABVD could be improved by the addition of new drugs 
such as brentuximab vedotin or checkpoint inhibitors (eg 
nivolumab, pembrolizumab). Combination of doxorubi-
cin (Adriamycin), vinblastine, and dacarbazine (AVD) 
plus brentuximab vedotin has been evaluated by Connors 
et al[14] in a phase III randomized study for stage III-IV 
HL. The 2-year modified PFS rate for ABVD with and with-
out brentuximab vedotin was 82.1% (95% CI 78.8-85.0) 
and 77.2% (95% CI 73.7-80.4), respectively, a difference 
of 4.9% points. There was no significant difference in OS 
at 2  years. Neutropenia, febrile neutropenia, and periph-
eral neuropathy were more frequent in the AVD plus bren-
tuximab arm. The combination of AVD plus nivolumab 
was recently evaluated in the Checkmate 205 study and 
showed an objective response rate of 84% and a 9-month 
F I G U R E  2  Kaplan-Meier curve for 
progression-free survival of all patients 
included in the four studies comparing 
ABVD and BEACOPP. ABVD, 
doxorubicin, bleomycin, vinblastine, and 
dacarbazine; BEACOPP, bleomycin, 
etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisone
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PFS of 92%.[15] A randomized study comparing AVD plus 
nivolumab and AVD plus brentuximab vedotin is expected 
to start recruitment by the end of 2019 (NCT03907488). 
Further improvement in disease control was more recently 
evaluated by PET-guided therapy after ABVD with the aim 
to reduce the burden of treatment, and therefore, toxicities 
related to bleomycine. Indeed, the response to the first two 
cycles of ABVD was reported as a major prognostic factor 
in advanced HL.[16] Johnson et al[17] showed that PET 
negative patients after two ABVD had a similar outcome 
when bleomycin was omitted in the next four cycles. In 
the same study, PET-positive patients after two cycles of 
ABVD had improved PFS (67.5%) and OS (87.8%) when 
intensified with BEACOPP, which compares favorably 
with historical controls.
Using these PET-adapted approaches have reduced both 
ABVD and BEACOPP toxicities as given in the four random-
ized studies used for the current analysis.
In conclusion, the current pooled analysis of four ran-
domized studies comparing ABVD vs BEACOPP did not 
show a clinically meaningful difference in OS in favor of 
the BEACOPP regimen. Death from HL remains the main 
concern with ABVD. The major cause of death following 
BEACOPP was secondary cancer, with secondary MDS/
AML being responsible of one-third of the deaths from sec-
ondary cancer. Admittedly, the 7 years of follow-up achieved 
in the current study remain still short when late toxicities 
are concerned and an even more prolonged follow-up of 
these studies will be needed to explore the final impact of 
BEACOPP and ABVD on fertility, secondary cancers, and 
OS.
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